KRAS and neoplasm: While NVP-BEZ235, a dual pan-PI3K and mTOR inhibitor, led to marked tumor regression in the PIK3CA-GEMM, it did not affect tumor growth significantly when treating the Kras-GEMM unless it was used in combination with a MEK inhibitor [38].